ClinicalTrials.gg

Program

BL-M08D1

A development code.

Its studies are mostly in Melanoma · Digestive System Neoplasms · Lymphoma, Large B-Cell, Diffuse · Nasopharyngeal Carcinoma · Squamous Cell Carcinoma of Head and Neck, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 2, since Aug 19, 20268 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical88 open or runningphase 2since Aug 19, 2026Dec 2, 2024Dec 2026phase 1 · NCT06718621

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 2, 2024First studies: 2 phase 1 studiesFirst studyNCT06718634, NCT06718621
  2. Aug 19, 20263 phase 2 studiesPhase 2 reachedNCT07780318, NCT07788950, NCT07793825
  3. Sep 8, 20263 phase 2 studiesNCT07818499, NCT07818486, NCT07841925

Ahead

  1. Dec 2026Primary completion: phase 1 study in Solid TumorNCT06718621
  2. Jun 2027Primary completion: phase 1 study in RecurrenceNCT06718634
  3. Dec 2028Primary completion: phase 2 study in MelanomaNCT07841925
  4. Dec 2028Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07818499

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07841925Melanoma · China2RecruitingDec 202830
NCT07818499Lymphoma, Large B-Cell, Diffuse · China2Not yet recruitingDec 2028204
NCT07818486Nasopharyngeal Carcinoma · China2Not yet recruitingDec 202830
NCT07793825Gynecological Tumors · China2Not yet recruitingDec 202890
NCT07788950Squamous Cell Carcinoma of Head and Neck · China2Not yet recruitingDec 202830
NCT07780318Digestive System Neoplasms · China2RecruitingDec 202860
NCT06718634Recurrence · China1RecruitingJun 202722
NCT06718621Solid Tumor · China1RecruitingDec 202622

How it is read

Names in the registry

  • “BL-M08D1”, 8 entries

Codes read as this program: BLM08D1.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.